Proton Therapy Facility at ACTREC, part of Tata Memorial Centre in Kharghar, has treated 1,000 cancer patients within three ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

In this week’s edition of InnovationRx, we look at Axsome’s growing pipeline, HistoSonics innovative cancer treatment, state ...

Shares in Clarity Pharmaceuticals Ltd (ASX: CU6) were trading more than 10% higher on good news about its prostate cancer ...

If the US FDA approves it, aglatimagene immunotherapy may become the first new therapy for men with localized prostate cancer in the past 2 decades.

KD Cancer Centre utilises MONACO® for precise cancer treatment planning, ensuring innovative and personalised approaches.

An 11-year-old boy from St Annes is undergoing treatment for a brain tumour and working with therapy dogs as part of his recovery. Dominic Barrow, who lives in St Annes, is currently receiving ...

A couple have shared their personal cancer journey. Natasha and her partner, Anthony from Bury, are among those featured in The Christie Charity’s latest Impact Report. Which highlights the real-world ...

The Christie Charity’s latest report highlights the impact of its support services, research and patient care on cancer ...

Median DFS was not reached in group receiving aglatimagene plus valacyclovir followed by EBRT after median follow-up of 50.3 months.

Values Company at $3.75 Billion and Funds Development of Additional Clinical ApplicationsMINNEAPOLIS--(BUSINESS ...

Adding an experimental immunotherapy to radiation treatment may extend disease-free survival in men with localized intermediate- or high-risk prostate cancer, according to a phase 3 trial. If approved ...